Home > You searched for cnsp > Page 18

Search Results for: cnsp

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Agreement for Upcoming Berubicin Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, have entered into an agreement for WPD to obtain Investigational Medicinal Product (“IMP”) classification for Berubicin for its use in upcoming  clinical trials. … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Agreement for Upcoming Berubicin Clinical Trials”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Transformation as Berubicin Becomes Subject of Active Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. The company’s pipeline includes Berubicin for the treatment of patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently focused on … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Transformation as Berubicin Becomes Subject of Active Clinical Trials”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Key Milestone, Progress Toward Collaborative Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Key Milestone, Progress Toward Collaborative Clinical Trials”

CNS Pharmaceuticals (NASDAQ: CNSP) Celebrates IND Status, Prepares to Launch Brain Cancer Drug Trials

Brain cancer drug developer CNS Pharmaceuticals is celebrating recent news that the U.S. Food and Drug Administration (“FDA”) granted investigational new drug (“IND”) status to CNS Pharmaceuticals’ leading candidate for fighting glioblastomas Glioblastomas are a class of aggressive brain cancers with no known cure and a median life expectancy of 14 to 16 months following … Continue reading “CNS Pharmaceuticals (NASDAQ: CNSP) Celebrates IND Status, Prepares to Launch Brain Cancer Drug Trials”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) on the Verge of Changing History with Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, has set sights on an encouraging future for glioblastoma patients with its upcoming Phase 2 trial of Berubicin. The article detailing this groundbreaking news quoted the company’s CEO John … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) on the Verge of Changing History with Berubicin”

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Discusses Product Pipeline, Clinical Trial Plans, at H.C. Wainwright Bioconnect 2021 Virtual Conference

Company will initiate a Phase II adult trial for Berubicin this year focused on patients with glioblastoma multiforme WPD, a CNS sub-license partner, will be commencing a parallel Phase II adult trial and the first-ever pediatric Berubicin trial Additional clinical trials are in the pipeline, including one for the company’s newest drug candidate, WP1244, and … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Discusses Product Pipeline, Clinical Trial Plans, at H.C. Wainwright Bioconnect 2021 Virtual Conference”

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with New Berubicin Clinical Trials, Determined to Help Address Unmet Needs of GBM Patients

IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancers Company holds the exclusive worldwide license for Berubicin, the first anthracycline to cross the blood-brain barrier in the adult brain The GBM therapeutics market is … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with New Berubicin Clinical Trials, Determined to Help Address Unmet Needs of GBM Patients”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco shared the history of CNS Pharmaceuticals and provided an update on the company’s recent business … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at the H.C. Wainwright BioConnect 2021 Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO, John Climaco, will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The event is slated to be held from Jan. 11-14, 2021, with … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at the H.C. Wainwright BioConnect 2021 Conference”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shares Objectives for Berubicin Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently hosted a webinar to discuss the clinical design for its upcoming Phase 2 trial. The trial will study its lead drug candidate, Berubicin, for the treatment of glioblastoma … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shares Objectives for Berubicin Phase 2 Trial”

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered

512.354.7000

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .